Treatment of knee osteoarthritis with a topical non-steroidal antiinflammatory drug. Results of a randomized, double-blind, placebo-controlled study on the efficacy and safety of a 5% ibuprofen cream

Drugs under Experimental and Clinical Research

Volumn 27, Issue 5-6, 2001, Pages 209-221

  Rovensky J ^a   Micekova D ^a   Gubzova Z ^a   Fimmers, R ^a   Lenhard, G ^a   Vogtle Junkert U ^a   Schreyger, F ^a  

^a NATIONAL INSTITUTE OF RHEUMATIC DISEASES   (Slovakia)

Author keywords

[No Author keywords available]

Indexed keywords

IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; KNEE OSTEOARTHRITIS; KNEE RADIOGRAPHY; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PAIN; PAIN ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SELF EVALUATION; STATISTICAL ANALYSIS;

ADMINISTRATION, TOPICAL; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IBUPROFEN; MALE; MIDDLE AGED; MOVEMENT; OINTMENTS; OSTEOARTHRITIS, KNEE; PAIN MEASUREMENT; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0035573982     PISSN: 03786501     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Topische anwendung verträglicher?
2. Etude clinique de l'efficacité et de la tolérance de l'ibuprofène percutané dans le traitement des tendinites
3. Etude clinique de l'efficacité et de la tolérance de l'ibuprofène percutané dans le traitement symptematique de l'arthrese des petites articulations
4. Lokale ibuprofen-therapie
5. Nach zwei wochen wieder schmerzfrei beweglich
6. Dolgit creme bei unfall- und sportverletzungen
7. Noch schneller durch Iontophorese. Ergebnisse einer AWB mit einer 5%igen Ibuprofen-Creme
8. Alleinige perkutane Rheumatherapie: Alternative zur oralen Therapie?
9. Development of criteria for the classification and reporting of osteoarthritis: Classification of osteoarthritis of the knee
10. Radiological assessment of osteoarthritis
11. Evaluation of experiments with adaptive interim analyses
12. Dissociation between the antinociceptive and anti-inflammatory effects of the non-steroidal antiinflammatory drugs, A survey of their analgesic efficacy
13. Nonsteroidal antiinflammatory drug use in relation to major upper gastrointestinal bleeding
14. Nutzen und risiken von nichtsteroidalen antiphlogistika (NSA) bei systemischer und lokaler anwendung
15. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal antiinflammatory drugs
16. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs
17. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure
18. Quantitative systematic review of topically applied non-steroidal anti-inflammatory drugs
19. Topical NSAIDs for musculoskeletal conditions: A review of the literature
20. Topical non-steroidal anti-inflammatory drugs and admission to hospital for upper gastrointestinal bleeding and perforation: A record linkage case-control study
21. Oral versus topical NSAIDs in rheumatic diseases
22. Zur perkutanen kinetik von ibuprofen aus einer cremezubereitung
23. Spezielle untersuchungen zur perkutanen kinetik von ibuprofen
24. Zur perkutanen kinetik von ibuprofen
25. Direktpenetration von NSAR-enthaltenden topika
26. Visual analogue scales
27. The algofunctional indices for hip and knee osteoarthritis
28. Indices of severity for osteoarthritis of the hip and of the knee. Validation. Value in comparison with other assessment tests
29. The minimum chnically important difference in physician-assigned visual analog pain scores
30. The clinical significance of reported changes in pain severity
31. Does the clinically significant difference in visual analog pain scores vary with gender, age, or cause of pain?
32. Minimum important difference between patients with rheumatoid arthritis: The patient's perspective
33. Renale nebenwirkungen nichtsteroidater antirheumatika
34. Nonsteroidal anti-inflammatory drugs and hospitalization for acute renal failure
35. Renal disease and use of topical non-steroidal anti-inflammatory drugs
36. Renal failure after topical use of NSAIDs